These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 11814769)
1. Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. Lentino JR; Krasnicka B Int J Antimicrob Agents; 2002 Jan; 19(1):61-6. PubMed ID: 11814769 [TBL] [Abstract][Full Text] [Related]
2. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB; Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688 [TBL] [Abstract][Full Text] [Related]
3. Is gentamicin safe and effective for severe community-acquired pneumonia? An 8-year retrospective cohort study. Brereton CJ; Lennon D; Browning S; Dunn E; Ferguson JK; Davis JS Int J Antimicrob Agents; 2018 Jun; 51(6):862-866. PubMed ID: 29410326 [TBL] [Abstract][Full Text] [Related]
4. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768 [TBL] [Abstract][Full Text] [Related]
5. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus. So W; Crandon JL; Nicolau DP Intern Emerg Med; 2016 Jun; 11(4):545-51. PubMed ID: 26531307 [TBL] [Abstract][Full Text] [Related]
6. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis. Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381 [TBL] [Abstract][Full Text] [Related]
7. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787 [TBL] [Abstract][Full Text] [Related]
8. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460 [TBL] [Abstract][Full Text] [Related]
9. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913 [TBL] [Abstract][Full Text] [Related]
13. Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital. Fok MC; Kanji Z; Mainra R; Boldt M Can Respir J; 2002; 9(4):247-52. PubMed ID: 12195270 [TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542 [TBL] [Abstract][Full Text] [Related]
15. [Treatment for Legionnaires' disease. Macrolides or quinolones?]. Falcó V; Molina I; Juste C; Crespo M; Almirante B; Pigrau C; Ferrer A; Bravo C; Palomar M; Pahissa A Enferm Infecc Microbiol Clin; 2006; 24(6):360-4. PubMed ID: 16792936 [TBL] [Abstract][Full Text] [Related]
16. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. Oster G; Berger A; Edelsberg J; Weber DJ J Med Econ; 2013; 16(6):809-19. PubMed ID: 23574431 [TBL] [Abstract][Full Text] [Related]
17. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876 [TBL] [Abstract][Full Text] [Related]
18. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients. Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748 [TBL] [Abstract][Full Text] [Related]
19. Does sputum culture affect the management and/or outcome of community-acquired pneumonia? Shariatzadeh MR; Marrie TJ East Mediterr Health J; 2009; 15(4):792-9. PubMed ID: 20187530 [TBL] [Abstract][Full Text] [Related]
20. Treatment of community-acquired pneumonia in hospitalised patients. Mulazimoglu L Int J Antimicrob Agents; 2001; 18 Suppl 1():S63-70. PubMed ID: 11574198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]